Condition: Diffuse Astrocytoma, IDH-Mutant · Glioblastoma, IDH-wildtype · Brain Metastases, Adult · Sponsor: Neonc Technologies, Inc.
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the safety, pharmacokinetics and efficacy of a repeated dose regimen of NEO212 when given with select SOC for the treatment of solid tumor patients with radiographically confirmed uncontrolled metastases to the brain. The study will have three phases, Phase 1, Phase 2a and Phase 2b.
This description comes directly from the study's public registry record.
Christopher Beardmore · 224 218 2408 · chris@anovaevidence.com
Chloe Richmond · 224 218 2408 · chloe@anovaevidence.com
Always discuss trial participation with your own doctor first.
| Precision NextGen Oncology | Beverly Hills, California, United States | Recruiting |
| OPN Healthcare, Inc | Glendale, California, United States | Recruiting |
| University of Southern California | Los Angeles, California, United States | Recruiting |
| MDR Core Network | Boynton Beach, Florida, United States | Recruiting |
| Vanderbilt University Medical Center | Nashville, Tennessee, United States | Recruiting |
| Baylor, Scott and White Research Institute | Dallas, Texas, United States | Recruiting |
| Northwest Medical Specialties | Tacoma, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06047379